Cargando…

Structure of SARS-CoV-2 Spike Glycoprotein for Therapeutic and Preventive Target

The global crisis caused by the coronavirus disease 2019 (COVID-19) led to the most significant economic loss and human deaths after World War II. The pathogen causing this disease is a novel virus called the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of December 2020, there ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Jaewoo, Jhun, Hyunjhung, Choi, Yeo-Ok, Taitt, Afeisha S., Bae, Suyoung, Lee, Youngmin, Song, Chang-seon, Yeom, Su Cheong, Kim, Soohyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Immunologists 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937506/
https://www.ncbi.nlm.nih.gov/pubmed/33728101
http://dx.doi.org/10.4110/in.2021.21.e8
_version_ 1783661405264674816
author Hong, Jaewoo
Jhun, Hyunjhung
Choi, Yeo-Ok
Taitt, Afeisha S.
Bae, Suyoung
Lee, Youngmin
Song, Chang-seon
Yeom, Su Cheong
Kim, Soohyun
author_facet Hong, Jaewoo
Jhun, Hyunjhung
Choi, Yeo-Ok
Taitt, Afeisha S.
Bae, Suyoung
Lee, Youngmin
Song, Chang-seon
Yeom, Su Cheong
Kim, Soohyun
author_sort Hong, Jaewoo
collection PubMed
description The global crisis caused by the coronavirus disease 2019 (COVID-19) led to the most significant economic loss and human deaths after World War II. The pathogen causing this disease is a novel virus called the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of December 2020, there have been 80.2 million confirmed patients, and the mortality rate is known as 2.16% globally. A strategy to protect a host from SARS-CoV-2 is by suppressing intracellular viral replication or preventing viral entry. We focused on the spike glycoprotein that is responsible for the entry of SARS-CoV-2 into the host cell. Recently, the US Food and Drug Administration/EU Medicines Agency authorized a vaccine and antibody to treat COVID-19 patients by emergency use approval in the absence of long-term clinical trials. Both commercial and academic efforts to develop preventive and therapeutic agents continue all over the world. In this review, we present a perspective on current reports about the spike glycoprotein of SARS-CoV-2 as a therapeutic target.
format Online
Article
Text
id pubmed-7937506
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Korean Association of Immunologists
record_format MEDLINE/PubMed
spelling pubmed-79375062021-03-15 Structure of SARS-CoV-2 Spike Glycoprotein for Therapeutic and Preventive Target Hong, Jaewoo Jhun, Hyunjhung Choi, Yeo-Ok Taitt, Afeisha S. Bae, Suyoung Lee, Youngmin Song, Chang-seon Yeom, Su Cheong Kim, Soohyun Immune Netw Review Article The global crisis caused by the coronavirus disease 2019 (COVID-19) led to the most significant economic loss and human deaths after World War II. The pathogen causing this disease is a novel virus called the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of December 2020, there have been 80.2 million confirmed patients, and the mortality rate is known as 2.16% globally. A strategy to protect a host from SARS-CoV-2 is by suppressing intracellular viral replication or preventing viral entry. We focused on the spike glycoprotein that is responsible for the entry of SARS-CoV-2 into the host cell. Recently, the US Food and Drug Administration/EU Medicines Agency authorized a vaccine and antibody to treat COVID-19 patients by emergency use approval in the absence of long-term clinical trials. Both commercial and academic efforts to develop preventive and therapeutic agents continue all over the world. In this review, we present a perspective on current reports about the spike glycoprotein of SARS-CoV-2 as a therapeutic target. The Korean Association of Immunologists 2021-02-19 /pmc/articles/PMC7937506/ /pubmed/33728101 http://dx.doi.org/10.4110/in.2021.21.e8 Text en Copyright © 2021. The Korean Association of Immunologists https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Hong, Jaewoo
Jhun, Hyunjhung
Choi, Yeo-Ok
Taitt, Afeisha S.
Bae, Suyoung
Lee, Youngmin
Song, Chang-seon
Yeom, Su Cheong
Kim, Soohyun
Structure of SARS-CoV-2 Spike Glycoprotein for Therapeutic and Preventive Target
title Structure of SARS-CoV-2 Spike Glycoprotein for Therapeutic and Preventive Target
title_full Structure of SARS-CoV-2 Spike Glycoprotein for Therapeutic and Preventive Target
title_fullStr Structure of SARS-CoV-2 Spike Glycoprotein for Therapeutic and Preventive Target
title_full_unstemmed Structure of SARS-CoV-2 Spike Glycoprotein for Therapeutic and Preventive Target
title_short Structure of SARS-CoV-2 Spike Glycoprotein for Therapeutic and Preventive Target
title_sort structure of sars-cov-2 spike glycoprotein for therapeutic and preventive target
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937506/
https://www.ncbi.nlm.nih.gov/pubmed/33728101
http://dx.doi.org/10.4110/in.2021.21.e8
work_keys_str_mv AT hongjaewoo structureofsarscov2spikeglycoproteinfortherapeuticandpreventivetarget
AT jhunhyunjhung structureofsarscov2spikeglycoproteinfortherapeuticandpreventivetarget
AT choiyeook structureofsarscov2spikeglycoproteinfortherapeuticandpreventivetarget
AT taittafeishas structureofsarscov2spikeglycoproteinfortherapeuticandpreventivetarget
AT baesuyoung structureofsarscov2spikeglycoproteinfortherapeuticandpreventivetarget
AT leeyoungmin structureofsarscov2spikeglycoproteinfortherapeuticandpreventivetarget
AT songchangseon structureofsarscov2spikeglycoproteinfortherapeuticandpreventivetarget
AT yeomsucheong structureofsarscov2spikeglycoproteinfortherapeuticandpreventivetarget
AT kimsoohyun structureofsarscov2spikeglycoproteinfortherapeuticandpreventivetarget